@article {189181,
	title = {High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter study.},
	journal = {Expert review of gastroenterology \& hepatology},
	volume = {13},
	year = {2019},
	pages = {907-914},
	abstract = {<p> Evaluation of~the efficacy and safety of sofosbuvir/daclatasvir/ribavirin (SOF/DCV/RBV) in treating non-sustained~virological responders (non-SVR12) to prior sofosbuvir-based~therapy, in absence of RAS testing in mass treatment, and determination of the optimal timing to start re-treatment.  Real-life~prospective observational study included prior non-responders to 24-weeks~SOF-RBV~(n~=~679, 67\%) or 12-weeks~SOF- RBV- PEG (n~=~335, 33\%). Patients were re-treated with daily SOF/DCV/RBV for 12 (n~=~270) or 24~weeks (n~=~744). The primary efficacy endpoint was SVR12. The primary safety endpoints were reported adverse events (AEs) from baseline to SVR12 time point.  We included 1,014 patients [age 52~{\textpm}~9~years, 58.48\% men]. Cirrhosis was documented in 46.98\%~and 27.5\% of SOF-RBV~and SOF-RBV-PEG~non-responders~respectively. Overall, SVR12 was 90.6\% [92.2\% for 12~weeks therapy and 90.05\% for 24~weeks therapy]. Mild AEs occurred in 5.13\% (n=52)~and~3.1\% (n=32)~discontinued treatment including eight on-treatment~mortalities. Higher baseline FIB-4 and shorter interval before starting retreatment~(\&lt;6~months) were independent predictors of non-SVR12 on multivariate regression analysis.  SOF/DCV/RBV is an effective and safe treatment option for non-responders~to prior sofosbuvir-based~therapy. Six months interval before retreatment is optimal for achieving favorable SVR.</p>
},
	author = {Darweesh, Samar K. and Kadry Elsaeed and Heba Omar and Maissa El Raziky and Wafaa elakel and Magdy El Serafy and Ismail, Sohier Ahmed and Gomaa, Ahmed A and Mai Mehrez and Elkassas, Mahamed and Abdullah, Mohamed and Shaker, Mohammed Kamal and Gamal Esmat and ElShazly, Yehia and Wahid Doss and Waked, Imam}
}
